查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878881

抗癌藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按適應症、藥物、給藥途徑、最終用戶、地區和競爭格局分類，2020-2030年預測

Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Drug, By Route of Administration, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球抗癌藥物市場規模為1,799.3億美元，預計2030年將以5.25%的複合年成長率成長至2,445.9億美元。抗癌藥物是專門用於抑製或摧毀惡性細胞的藥物，是各種癌症治療策略的基石。市場擴張的主要促進因素包括全球癌症發生率的不斷攀升、易患腫瘤疾病的老齡人口的增加，以及醫學研究的持續進步帶來的新型治療突破。

市場概覽
預測期 2026-2030
2024年市場規模 1799.3億美元
2030年市場規模 2445.9億美元
2025-2030年複合年成長率 5.25%
成長最快的細分市場 乳癌
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球抗癌藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症分類（乳癌、血液癌症、攝護腺癌、胃腸道癌症、婦科癌症、肺癌、其他）
    • 依藥物分類（細胞毒性藥物、荷爾蒙療法、標靶治療、其他）
    • 依給藥途徑（口服、注射、其他）
    • 按最終使用者（醫院和診所、門診中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美抗癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲抗癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球抗癌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • AstraZeneca plc
  • Sanofi SA
  • Bayer AG

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20973

The Global Anticancer Drug Market, valued at USD 179.93 Billion in 2024, is projected to experience a CAGR of 5.25% to reach USD 244.59 Billion by 2030. Anticancer drugs represent pharmaceutical agents specifically formulated to inhibit or destroy malignant cells, serving as the cornerstone for various cancer treatment strategies. The market's expansion is primarily driven by the escalating global incidence of cancer, an expanding aging population predisposed to oncological diseases, and continuous advancements in medical research that foster novel therapeutic breakthroughs.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 179.93 Billion
Market Size 2030USD 244.59 Billion
CAGR 2025-20305.25%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

Key Market Drivers

The increasing global cancer incidence substantially propels the anticancer drug market. A growing patient population naturally leads to a higher demand for diagnostic tools and subsequent therapeutic interventions, from chemotherapy to advanced targeted therapies. This demographic shift intensifies the need for a continuous supply of effective pharmaceuticals, driving companies to expand their portfolios. According to the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases worldwide, indicating a vast and expanding patient pool requiring treatment. The persistent rise in various cancer types underscores the demand for innovative drug solutions.

Key Market Challenges

A significant challenge impeding the growth of the global anticancer drug market is the considerable cost associated with the development and provision of advanced therapies. These high costs directly restrict patient access and affordability, particularly within emerging economies. This limitation reduces the eligible patient population for novel treatments, thereby hampering market penetration and overall sales volumes globally.

Key Market Trends

The integration of artificial intelligence (AI) in oncology is profoundly reshaping drug discovery and development processes. AI algorithms can analyze vast datasets, identify novel drug targets, and predict compound efficacy with increased speed and accuracy compared to traditional methods. This technological advancement significantly reduces the time and cost associated with bringing new anticancer drugs to market, fostering a more efficient and productive pipeline. According to Silicon Valley Bank, biotech AI attracted $5.6 billion in 2024, constituting nearly 30% of healthcare startup funding, reflecting a substantial increase driven by significant investment deals. This influx of capital underscores the industry's confidence in AI's transformative potential. For example, Insilico Medicine announced in June 2023 that its small molecule inhibitor drug candidate, INS018_055, an entirely AI-discovered and AI-designed drug, entered a phase 2 clinical trial for idiopathic pulmonary fibrosis, demonstrating the tangible progress of AI in therapeutic advancement.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • AstraZeneca plc
  • Sanofi S.A.
  • Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

  • Breast Cancer
  • Blood Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Gynaecologic Cancer
  • Lung Cancer
  • Others

Anticancer Drug Market, By Drug:

  • Cytotoxics
  • Hormonal Therapy
  • Targeted Therapy
  • Others

Anticancer Drug Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Anticancer Drug Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Anticancer Drug Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anticancer Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Lung Cancer, Others)
    • 5.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Anticancer Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Drug
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anticancer Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Drug
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Anticancer Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Drug
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Anticancer Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Drug
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User

7. Europe Anticancer Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Drug
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anticancer Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Drug
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. France Anticancer Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Drug
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Anticancer Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Drug
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Anticancer Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Drug
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Anticancer Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Drug
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User

8. Asia Pacific Anticancer Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Drug
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anticancer Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Drug
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. India Anticancer Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Drug
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Anticancer Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Drug
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Anticancer Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Drug
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Anticancer Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Drug
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User

9. Middle East & Africa Anticancer Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Drug
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anticancer Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Drug
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Anticancer Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Drug
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Anticancer Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Drug
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. South America Anticancer Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Drug
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anticancer Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Drug
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Anticancer Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Drug
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Anticancer Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Drug
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anticancer Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Genentech, Inc.
  • 15.3. Novartis AG
  • 15.4. Pfizer Inc.
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. GlaxoSmithKline plc.
  • 15.7. Eli Lilly and Company (India) Pvt. Ltd.
  • 15.8. AstraZeneca plc
  • 15.9. Sanofi S.A.
  • 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer